New diagnostic and therapeutic approaches for preventing the progression of diabetic retinopathy

Journal of Diabetes Research

Volumn 2016, Issue , 2016, Pages

  Park, Young Gun ^a   Roh, Young Jung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A;

CORTICOSTEROID THERAPY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; EARLY DIAGNOSIS; EYE FUNDUS; HUMAN; INTRAVITREAL IMPLANT; LASER COAGULATION; OPHTHALMIC LASER; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA FLUORESCEIN ANGIOGRAPHY; REVIEW; VITRECTOMY; ANTAGONISTS AND INHIBITORS; FLUORESCENCE ANGIOGRAPHY; LOW LEVEL LASER THERAPY;

DIABETIC RETINOPATHY; DISEASE PROGRESSION; EARLY DIAGNOSIS; FLUORESCEIN ANGIOGRAPHY; HUMANS; LOW-LEVEL LIGHT THERAPY; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84957054266     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2016/1753584     Document Type: Review

References (69)

1. R. L. Thomas, F. Dunstan, S. D. Luzio et al. , "Incidence of diabetic retinopathy in people with type 2 diabetesmellitus attending the diabetic retinopathy screening service for Wales: retrospective analysis," British Medical Journal, vol. 344, no. 7848, article e874, 2012.
2. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, "Global estimates of the prevalence of diabetes for 2010 and 2030," Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4-14, 2010.
3. E. S. Shin, C. M. Sorenson, and N. Sheibani, "Diabetes and retinal vascular dysfunction," Journal of Ophthalmic & Vision Research, vol. 9, no. 3, pp. 362-373, 2014.
4. A. M. A. El-Asrar, "Role of inflammation in the pathogenesis of diabetic retinopathy," Middle East African Journal of Ophthalmology, vol. 19, no. 1, pp. 70-74, 2012.
5. The Diabetic Retinopathy Study Research Group, "Preliminary report on effects of photocoagulation therapy," American Journal of Ophthalmology, vol. 81, no. 4, pp. 383-396, 1976.
6. E. Stefansson, T. Bek, M. Porta, N. Larsen, J. K. Kristinsson, and E. Agardh, "Screening and prevention of diabetic blindness," Acta Ophthalmologica Scandinavica, vol. 78, no. 4, pp. 374-385, 2000.
7. N. Cheung, P. Mitchell, and T. Y. Wong, "Diabetic retinopathy," The Lancet, vol. 376, no. 9735, pp. 124-136, 2010.
8. The Diabetic Retinopathy Study Research Group, "Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings," Ophthalmology, vol. 85, no. 1, pp. 82-106, 1978.
9. Early photocoagulation for diabetic retinopathy-ETDRS report number 9. Early Treatment Diabetic Retinopathy Study ResearchGroup," Ophthalmology 98, no. 5, supplement 766-785 1991.
10. Early Treatment Diabetic Retinopathy Study Research Group, "Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2," Ophthalmology, vol. 94, no. 7, pp. 761-774, 1987.
11. M. S. Blumenkranz, "The evolution of laser therapy in ophthalmology: a perspective on the interactions between photons, patients, physicians, and physicists: the LXX Edward Jackson Memorial Lecture," American Journal of Ophthalmology, vol. 158, no. 1, pp. 12. e1-25. e1, 2014.
12. M. Matsumoto, N. Yoshimura, and Y. Honda, "Increased production of transforming growth factor-β2 from cultured human retinal pigment epithelial cells by photocoagulation," Investigative Ophthalmology and Visual Science, vol. 35, no. 13, pp. 4245-4252, 1994.
13. C. Sramek, M. Mackanos, R. Spitler et al. , "Non-damaging retinal phototherapy: dynamic range of heat shock protein expression," InvestigativeOphthalmologyandVisual Science, vol. 52, no. 3, pp. 1780-1787, 2011.
14. N. Bhagat, R. A. Grigorian, A. Tutela, and M. A. Zarbin, "Diabetic macular edema: pathogenesis and treatment," Survey of Ophthalmology, vol. 54, no. 1, pp. 1-32, 2009.
15. A. Arnarsson and E. Stefansson, "Laser treatment and themechanism of edema reduction in branch retinal vein occlusion," Investigative Ophthalmology and Visual Science, vol. 41, no. 3, pp. 877-879, 2000.
16. N. Ogata, A. Ando, M. Uyama, and M. Matsumura, "Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells," Graefes Archive for Clinical and Experimental Ophthalmology, vol. 239, no. 2, pp. 87-95, 2001.
17. N. Ogata, J. Tombran-Tink, N. Jo, D. Mrazek, and M. Matsumura, "Upregulation of pigment epithelium-derived factor after laser photocoagulation," American Journal of Ophthalmology, vol. 132, no. 3, pp. 427-429, 2001.
18. D. S. Fong, A. Girach, and A. Boney, "Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review," Retina, vol. 27, no. 7, pp. 816-824, 2007.
19. T. Qaum, Q. Xu, A. M. Joussen et al. , "VEGF-initiated bloodretinal barrier breakdown in early diabetes," Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2408-2413, 2001.
20. P. Massin, F. Bandello, J. G. Garweg et al. , "Safety and efficacy of ranibizumab in diabeticmacular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study," Diabetes Care, vol. 33, no. 11, pp. 2399-2405, 2010.
21. P. Mitchell, F. Bandello, U. Schmidt-Erfurth et al. , "The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema," Ophthalmology, vol. 118, no. 4, pp. 615-625, 2011.
22. The Diabetic Retinopathy Clinical Research Network, "Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema," The New England Journal of Medicine, vol. 372, no. 13, pp. 1193-1203, 2015.
23. M. J. Elman, H. Qin, L. P. Aiello et al. , "Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results," Ophthalmology, vol. 119, no. 11, pp. 2312-2318, 2012.
24. J. A. Ford, A. Elders, D. Shyangdan, P. Royle, and N. Waugh, "The relative clinical effectiveness of ranibizumab and bevacizumab in diabeticmacular oedema: an indirect comparison in a systematic review," British Medical Journal, vol. 345, no. 7875, Article ID e5182, 2012.
25. C. Costagliola, L. Agnifili, B. Arcidiacono et al. , "Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration," ExpertOpinion on BiologicalTherapy, vol. 12, no. 10, pp. 1299-1313, 2012.
26. F. Bandello, C. Preziosa, G. Querques, and R. Lattanzio, "Update of intravitreal steroids for the treatment of diabetic macular edema," Ophthalmic Research, vol. 52, no. 2, pp. 89-96, 2014.
27. M. M. Nentwich andM. W. Ulbig, "The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy," Deutsches Arzteblatt International, vol. 109, no. 37, pp. 584-590, 2012.
28. W. B. Messenger, R. M. Beardsley, and C. J. Flaxel, "Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema," Drug Design, Development and Therapy, vol. 7, pp. 425-434, 2013.
29. M. DutraMedeiros, M. Postorino, R. Navarro, J. Garcia-Arumi, C. Mateo, and B. Corcostegui, "Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema," Ophthalmologica, vol. 231, no. 3, pp. 141-146, 2014.
30. W. M. Amoaku, S. Saker, and E. A. Stewart, "A review of therapies for diabeticmacular oedema and rationale for combination therapy," Eye, vol. 29, no. 9, pp. 1115-1130, 2015.
31. S. Guigou, S. Pommier, F. Meyer et al. , "Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema," Ophthalmologica, vol. 233, no. 3-4, pp. 169-175, 2015.
32. P. A. Pearson, T. L. Comstock, M. Ip et al. , "Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial," Ophthalmology, vol. 118, no. 8, pp. 1580-1587, 2011.
33. J. O. Mason III, C. T. Colagross, and R. Vail, "Diabetic vitrectomy: risks, prognosis, future trends," Current Opinion in Ophthalmology, vol. 17, no. 3, pp. 281-285, 2006.
34. M. P. Simunovic, A. P. Hunyor, and I.-V. Ho, "Vitrectomy for diabetic macular edema: a systematic review and meta-analysis," Canadian Journal of Ophthalmology, vol. 49, no. 2, pp. 188-195, 2014.
35. Diabetic Retinopathy Clinical ResearchNetworkWriting Committee, J. A. Haller, H. Qin et al. , "Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction," Ophthalmology, vol. 117, no. 6, pp. 1087-1093. e3, 2010.
36. C. J. Flaxel, A. R. Edwards, L. P. Aiello et al. , "Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network," Retina, vol. 30, no. 9, pp. 1488-1495, 2010.
37. J. G. Arumi, A. Boixadera, V. Martinez-Castillo, and B. Corcostegui, "Transconjunctival sutureless 23-gauge vitrectomy for diabetic retinopathy. Review," Current Diabetes Reviews, vol. 5, no. 1, pp. 63-66, 2009.
38. D. H. Park, J. P. Shin, and S. Y. Kim, "Comparison of clinical outcomes between 23-gauge and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy," Retina, vol. 30, no. 10, pp. 1662-1670, 2010.
39. D. K. Newman, "Surgical management of the late complications of proliferative diabetic retinopathy," Eye, vol. 24, no. 3, pp. 441-449, 2010.
40. A. Kaines, S. Oliver, S. Reddy, and S. D. Schwartz, "Ultrawide angle angiography for the detection and management of diabetic retinopathy," International Ophthalmology Clinics, vol. 49, no. 2, pp. 53-59, 2009.
41. A. Manivannan, J. Plskova, A. Farrow, S. Mckay, P. F. Sharp, and J. V. Forrester, "Ultra-wide-field fluorescein angiography of the ocular fundus," American Journal of Ophthalmology, vol. 140, no. 3, pp. 525-527, 2005.
42. M. M. Wessel, G. D. Aaker, G. Parlitsis, M. Cho, D. J. DAmico, and S. Kiss, "Ultra-wide-field angiography improves the detection and classification of diabetic retinopathy," Retina, vol. 32, no. 4, pp. 785-791, 2012.
43. A. C. Sull, L. N. Vuong, L. L. Price et al. , "Comparison of spectral/ fourier domain optical coherence tomography instruments for assessment of normalmacular thickness," Retina, vol. 30, no. 2, pp. 235-245, 2010.
44. B. L. Sikorski, G. Malukiewicz, J. Stafiej, H. Lesiewska-Junk, and D. Raczynska, "The diagnostic function of OCT in diabetic maculopathy," Mediators of Inflammation, vol. 2013, Article ID 434560, 12 pages, 2013.
45. R. F. Spaide, H. Koizumi, and M. C. Pozonni, "Enhanced depth imaging spectral-domain optical coherence tomography," American Journal ofOphthalmology, vol. 146, no. 4, pp. 496-500, 2008.
46. A. Unterhuber, B. Povazay, B. Hermann, H. Sattmann, A. Chavez-Pirson, and W. Drexler, "In vivo retinal optical coherence tomography at 1040 nm-enhanced penetration into the choroid," Optics Express, vol. 13, no. 9, pp. 3252-3258, 2005.
47. Y. Jia, O. Tan, J. Tokayer et al. , "Split-spectrum amplitudedecorrelation angiography with optical coherence tomography," Optics Express, vol. 20, no. 4, pp. 4710-4725, 2012.
48. A. Ishibazawa, T. Nagaoka, A. Takahashi et al. , "Optical coherence tomography angiography in diabetic retinopathy: a prospective pilot study," American Journal of Ophthalmology, vol. 160, no. 1, pp. 35-44. e31, 2015.
49. B. S. Gerendas, S. M. Waldstein, C. Simader et al. , "Threedimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography and correlation with the level of diabetic macular edema," American Journal of Ophthalmology, vol. 158, no. 5, pp. 1039-1048, 2014.
50. C. V. Regatieri, L. Branchini, J. Carmody, J. G. Fujimoto, and J. S. Duker, "Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography," Retina, vol. 32, no. 3, pp. 563-568, 2012.
51. J. K. Luttrull and G. Dorin, "Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabeticmacular edema: a review, CurrentDiabetes Reviews, vol. 8, no. 4, pp. 274-284, 2012.
52. J. K. Luttrull, D. C. Musch, and M. A. Mainster, "Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema," British Journal of Ophthalmology, vol. 89, no. 1, pp. 74-80, 2005.
53. J. K. Luttrull and S. H. Sinclair, "Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabeticmacular edema ineyeswithgoodvisual acuity," Retina, vol. 34, no. 10, pp. 2010-2020, 2014.
54. L. Pelosini, R. Hamilton, M. Mohamed, A. P. Hamilton, and J. Marshall, "Retina rejuvenation therapy for diabetic macular EDEMA: a pilot study," Retina, vol. 33, no. 3, pp. 548-558, 2013.
55. J. Roider, S. H. M. Liew, C. Klatt et al. , "Selective retina therapy (SRT) for clinically significant diabeticmacular edema," Graefes Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 9, pp. 1263-1272, 2010.
56. Y.-G. Park, E. Seifert, Y. J. Roh, D. Theisen-Kunde, S. Kang, and R. Brinkmann, "Tissue response of selective retina therapy by means of a feedback-controlled energy ramping mode," Clinical and Experimental Ophthalmology, vol. 42, no. 9, pp. 846-855, 2014.
57. X. Gao and D. Xing, "Molecular mechanisms of cell proliferation induced by low power laser irradiation," Journal of Biomedical Science, vol. 16, article 4, 2009.
58. J. Roider, N. A. Michaud, T. J. Flotte, and R. Birngruber, "Response of the retinal pigment epithelium to selective photocoagulation," Archives of Ophthalmology, vol. 110, no. 12, pp. 1786-1792, 1992.
59. S. Sivaprasad, M. Elagouz, D. McHugh, O. Shona, and G. Dorin, "Micropulsed diode laser therapy: evolution and clinical applications," Survey of Ophthalmology, vol. 55, no. 6, pp. 516-530, 2010.
60. G. Dorin, "Subthreshold and micropulse diode laser photocoagulation," Seminars in Ophthalmology, vol. 18, no. 3, pp. 147-153, 2003.
61. J. K. Luttrull, D. C. Musch, and C. A. Spink, "Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy," Eye, vol. 22, no. 5, pp. 607-612, 2008.
62. S. Reddy, A. Hu, and S. D. Schwartz, "Ultrawide field fluorescein angiography guided Targeted Retinal Photocoagulation (TRP)," Seminars in Ophthalmology, vol. 24, no. 1, pp. 9-14, 2009.
63. The Japanese Society of Ophthalmic Diabetology and Subcommittee on the Study of Diabetic Retinopathy Treatment, "Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy," Japanese Journal of Ophthalmology, vol. 56, no. 1, pp. 52-59, 2012.
64. P. S. Silva, J. D. Cavallerano, J. K. Sun, A. Z. Soliman, L. M. Aiello, and L. P. Aiello, "Peripheral lesions identified by mydriatic ultrawide field imaging: distribution and potential impact on diabetic retinopathy severity," Ophthalmology, vol. 120, no. 12, pp. 2587-2595, 2013.
65. M. S. Ip, A. Domalpally, J. K. Sun, and J. S. Ehrlich, "Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy," Ophthalmology, vol. 122, no. 2, pp. 367-374, 2015.
66. L. Diaz-Flores, R. Gitoerrez, and H. Varela, "Angiogenesis: an update," Histology and Histopathology, vol. 9, no. 4, pp. 807-843, 1994.
67. A. N. Antoszyk, J. L. Gottlieb, R. Machemer, and D. L. Hatchell, "The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization," Graefes Archive for Clinical and ExperimentalOphthalmology, vol. 231, no. 1, pp. 34-40, 1993.
68. M. J. Elman, L. P. Aiello, R. W. Beck et al. , "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema," Ophthalmology, vol. 117, no. 6, pp. 1064. e35-1077. e35, 2010.
69. N. M. Bressler, A. R. Edwards, R. W. Beck et al. , "Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation," Archives of Ophthalmology, vol. 127, no. 12, pp. 1566-1571, 2009.